中国药业2024，Vol.33Issue(13)：107-110,4.DOI:10.3969/j.issn.1006-4931.2024.13.026
免疫治疗联合贝伐珠单抗抗血管生成双靶治疗对老年晚期肺腺癌患者近期临床疗效及安全性的影响
Short-Term Clinical Efficacy and Safety of Immunotherapy Combined with Anti-Angiogenic Dual-Target Therapy in the Treatment of Elderly Patients with Advanced Lung Adenocarcinoma
摘要
Abstract
Objective To investigate the effect of immunotherapy combined with anti-angiogenic dual-target therapy on the short-term clinical efficacy,immune function,and clinical safety in elderly patients with advanced lung adenocarcinoma.Methods Sixty patients(≥60 years)with stage Ⅳ lung adenocarcinoma admitted to the hospital from April to December 2022 were selected and randomly divided into the combination group and the control group,with 30 cases in each group.The patients in the two groups were treated with standard chemotherapy combined with either carrilizumab or xindirizumab,on this basis,the patients in the combination group were treated with bevacizumab.Both groups were treated for 9 weeks.Results The objective response rate(ORR)in the combination group was 36.67%,which was significantly higher than 13.33% in the control group(P<0.05).The disease control rate(DCR)in the combination group was 86.67%,which was higher than 73.33% in the control group,but the difference was not statistically significant(P>0.05).After treatment,the T lymphocyte subsets CD3+,CD4+levels,and CD4+/CD8+significantly increased(P<0.05),while the CD8+level significantly decreased in the two groups(P<0.05),and the change in the combination group was more significant than that in the control group(P<0.05);the Karnofsky function(KPS)score in the two groups significantly increased(P<0.05),and that in the combination group was significantly higher than that in the control group(P<0.05);the proportion of KPS score change with an increase level in the combination group was 90.00%,which was significantly higher than 66.67% in the control group(P<0.05).The incidence rates of gastrointestinal reactions,bone marrow transplantation,liver and kidney function damage,hematotoxicity,and peripheral neurotoxicity between the two groups were comparable(P>0.05).Conclusion Immunotherapy combined with anti-angiogenic dual-target therapy in the treatment of elderly patients with advanced lung adenocarcinoma has good short-term clinical efficacy and safety,which can significantly improve the patient's immune function and health status.关键词
肺腺癌/贝伐珠单抗/抗血管生成药物/免疫治疗/老年/晚期肿瘤Key words
lung adenocarcinoma/bevacizumab/antiangiogenic drugs/immunotherapy/elderly patients/advanced tumor分类
医药卫生引用本文复制引用
何学军,张晶,张志胜,包赟,崔林..免疫治疗联合贝伐珠单抗抗血管生成双靶治疗对老年晚期肺腺癌患者近期临床疗效及安全性的影响[J].中国药业,2024,33(13):107-110,4.基金项目
江苏省卫生健康委员会老年健康科研项目[LKM2022085]. （）
